Brief: Bioage Announces Additional Positive Interim Phase 1 Data For BGE-102, A Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential For Best-In-Class Hscrp Reduction In Participants With Elevated Cardiovascular Risk
12/01/2026 14:03
Jan 12 (Reuters) - BIOAGE Labs Inc BIOA.O: BIOAGE ANNOUNCES ADDITIONAL POSITIVE INTERIM PHASE 1 DATA FOR BGE-102, A NOVEL BRAIN-PENETRANT NLRP3 INHIBITOR, DEMONSTRATING POTENTIAL FOR BEST-IN-CLASS HSCRP REDUCTION IN PARTICIPANTS WITH ELEVATED CARDIOVASCULAR RISK BIOAGE LABS INC: BGE-102 WAS WELL TOLERATED WITH A FAVORABLE SAFETY PROFILE BIOAGE LABS INC - PHASE 1 DATA ANTICIPATED 1H 2026; PHASE 2A STUDY TO INITIATE 1H 2026 Source text: ID:nGNXLBt5B Further company coverage: BIOA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioAge Labs
See all newsBrief: Bioage Labs Announces First Participant Dosed In Quell-Dme, A Phase 2 Trial Of Bge-102, A Novel Oral Nlrp3 Inhibitor, In Diabetic Macular Edema
BioAge Labs, Inc. reports results for the quarter ended June 30 - Earnings Summary
BioAge Labs Q1 collaboration revenue beats estimates on Novartis collaboration
BioAge Labs full-year collaboration revenue beats estimates
U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP